ArticleInternational journal of cancer2014
Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.
Article in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.ImmunoTargets and therapy · 2026Review
- Targeting Podoplanin for the Treatment of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Review
- Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.Oncogene · 2021Article
- Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.Cancer science · 2021Article
- Role of Podoplanin-Positive Cells in Cardiac Fibrosis and Angiogenesis After Ischemia.Frontiers in physiology · 2021Review
- Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis.Cancers · 2018Review
- A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Oncotarget · 2018Article
- Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation.Scientific reports · 2017Article
- Platelet-activating factor podoplanin: from discovery to drug development.Cancer metastasis reviews · 2017Review
- Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.Cancer medicine · 2017Article
- The multifaceted role of podoplanin expression in hepatocellular carcinoma.European journal of histochemistry : EJH · 2017Article
- A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis.Scientific reports · 2017Article
- Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.Cancer medicine · 2017Article
- Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.Oncotarget · 2016Article
- Podoplanin serum and urine concentration in transitional bladder cancer.Cancer biomarkers : section A of Disease markers · 2016Article
- The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.Oncotarget · 2015Article
- miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.Cancer gene therapy · 2015Article
- Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2015Article
- A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet aggregation-inducing factor Aggrus, also known as podoplanin, is associated with tumor malignancy by promoting hematogenous metastasis. Aggrus overexpression has been reported in some tumor tissues including lung, esophagus, head and neck and brain. We here found the frequent upregulation of aggrus mRNA in urinary bladder cancers using cancer tissue panels from various organs. Immunohistochemical analysis confirmed Aggrus protein expression in urinary bladder cancers and suggested a positive correlation between Aggrus expression and metastatic tendency in bladder cancers. Endogenous expression of Aggrus protein on the cell surface was found in the mouse bladder cancer MBT-2 cell line and human bladder cancer SCaBER cell lines. Knockdown of Aggrus expression in MBT-2 cells decreased their ability to induce platelet aggregation and form pulmonary metastasis in syngeneic mouse models. Knockdown of Aggrus expression in the human bladder cancer SCaBER cells also attenuated their ability to induce platelet aggregation and form pulmonary metastasis in mice. Moreover, pulmonary metastasis of SCaBER cells was prevented by prior administration of our generated anti-Aggrus neutralizing monoclonal antibodies by attenuating their retention in lung. These results indicate that Aggrus plays an important role in bladder cancer metastasis. Thus, anti-Aggrus neutralizing antibodies would be useful for the prevention of hematogenous metastasis of Aggrus-positive bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.